MAGI Blue Ribbon Site: FOMAT Proven Clinical Research Excellence
FOMAT has been honored with MAGI Blue Ribbon Site designation as a charter member of the MAGI Blue Ribbon Sites Program, a recognition that reflects the organization’s sustained commitment to excellence in clinical research operations. The announcement was made by Norman Goldfarb, Chairman of MAGI, who noted that FOMAT is exceptional in finding locations and innovative methods that offer the diverse patient population the clinical research enterprise needs. According to the FDA, clinical research sites that maintain high quality standards are essential to producing the reliable data that supports drug development and approval.
What the MAGI Blue Ribbon Site Designation Represents
The MAGI Blue Ribbon Site program is administered by MAGI, an organization with more than 10,000 members representing clinical research sponsors, sites, and CROs. MAGI is dedicated to streamlining clinical research by standardizing best practices for clinical research operations, business management, and regulatory compliance across the industry.
Being designated a MAGI Blue Ribbon Site means a clinical research organization has demonstrated the characteristics that define excellence in the field. These include deep operational experience, organizational stability, rapid study start up capability, access to a large and diverse patient database, a consistent record of meeting or exceeding enrollment commitments, and the ability to generate high quality data within required timelines.
For FOMAT, the MAGI Blue Ribbon Site designation validates what the organization’s team has built through years of commitment to operational precision and patient centered research.
Nicholas Focil on the MAGI Blue Ribbon Site Achievement
Commenting on the recognition, Nicholas Focil, Managing Director, expressed appreciation to Norman Goldfarb and MAGI for the nomination and gave direct credit to the FOMAT team for earning it. As Focil stated, the credit belongs to an amazing team that has an unwillingness to settle. As a charter member of the MAGI Blue Ribbon Site program, FOMAT aims to lay the foundation for future sites that aspire to the same standard.
This perspective reflects a broader organizational philosophy: that clinical research is a demanding and often difficult business, and that excellence is something that must be actively pursued, demonstrated, and maintained, not simply claimed.
What MAGI Blue Ribbon Site Excellence Looks Like in Practice
The MAGI Blue Ribbon Site framework identifies a set of core characteristics that distinguish exceptional clinical research sites from the rest. A commitment to excellence begins with a shared vision and mastery of roles across every member of the research team. Accountability ensures that commitments made to sponsors are commitments kept. Collaboration between site staff, investigators, and sponsors creates the conditions for efficient, high-quality trial execution.
Beyond the operational mechanics, the MAGI Blue Ribbon Site designation recognizes something less tangible but equally important: pride in the work and genuine inspiration to rise above mediocrity. Clinical research that is done well produces data that shapes the medicines and therapies available to patients for generations. FOMAT’s designation reflects the team’s understanding of that responsibility.
About FOMAT
FOMAT is an international clinical research organization focused on innovating healthcare through diversity for underrepresented populations throughout the Americas. In the United States, FOMAT operates as a diverse Site Management Organization. In Latin America, FOMAT combines SMO capabilities with local CRO services, enabling the fastest study start up times in the region. This integrated structure allows FOMAT to get studies up and running quickly and efficiently across both sectors.
The MAGI Blue Ribbon Site recognition is one reflection of FOMAT’s broader commitment to quality, diversity, and innovation in clinical research. To learn more about FOMAT’s services and capabilities, visit our services page or explore our patient active studies.